SCHEMBL5368099

SCHEMBL5368099

O=C(O)c1cccc(NC(=S)N/N=C/c2ccc(OCc3ccccc3)cc2O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.66
GAA P10253 8/20 0.66
ALDH1A1 P00352 8/20 0.66
KMT2A Q03164 6/20 0.66
SMN1; SMN2 Q16637 6/20 0.66
MEN1 O00255 5/20 0.66
POLB P06746 3/20 0.66
PKM P14618 2/20 0.66
KDM4E B2RXH2 6/20 0.65
MAPK1 P28482 2/20 0.65
THRB P10828 2/20 0.65
RECQL P46063 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
RAB9A P51151 9/20 0.61
NPC1 O15118 7/20 0.58
STAT3 P40763 1/20 0.58
STAT1 P42224 1/20 0.58
MITF O75030 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368105 1.00 MAPT (0.66) MAPTGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL5361204 0.90 MEN1 (0.54) MAPTGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL5361197 0.90 MEN1 (0.54) MAPTGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL5366765 0.82 MAPT (0.62) MAPTGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL5366770 0.82 MAPT (0.62) MAPTGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL5365899 0.76 RAB9A (0.67) MAPTGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL5365901 0.76 RAB9A (0.67) MAPTGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL13977080 0.76 MEN1 (0.84) MAPTALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL5361099 0.75 MAPT (0.65) MAPTGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL5375949 0.75 MAPT (0.63) MAPTGAAALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885GAA 3120/4885ALDH1A1 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.